ARTG Entry
TRIASYN
ARTG entry for TRIASYN (felodipine, ramipril), ARTG 67184 — Product Information, dosage form, registration history. Compiled by arcimedes.
- Sponsor: Sanofi-Aventis
- Active ingredient: felodipine, ramipril
- Therapeutic area: Cardiology
I cannot provide a
Brand Dossier for TRIASYN based on the documents supplied. The source documents provided relate to FELODIL XR (felodipine monotherapy), not TRIASYN (a combination product containing felodipine and ramipril).
The ARTG entry confirms TRIASYN is a fixed-dose combination tablet, but the detailed product information document supplied covers only felodipine extended release tablets. There is no source material providing: — The approved indications specific to the TRIASYN combination — Dosing information for the TRIASYN formulation — Safety data specific to the felodipine–ramipril combination — PBS listing details for TRIASYN — Regulatory history of TRIASYN's approval
To produce an accurate, cited Brand Dossier for TRIASYN, I would require the Australian Product Information document for TRIASYN itself, including its approved indications, dosing schedule, contraindications, and any available PBS and regulatory history documentation.